Payment overview · 2025
General Payments
$324.30
18 reported records · 5 companies
Healthcare provider profile · identity verified
Barbara Rose Muniz, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DADE CITY, FL · NPI 1093163040
Verified facts
What the public records show
CMS Open Payments records show Barbara Rose Muniz, APRN received $324.30 in general payments during 2025 across 18 reported records.
Exact Sciences Corporation accounted for 32.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $106.07 | 32.7% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $94.23 | 29.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.53 | 14.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.20 | 12.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.27 | 11.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $324.30 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $106.07 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $94.23 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $75.45 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.53 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.20 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $38.27 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.27 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 44 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 329 | 114 |
| Lisinopril | Lisinopril | 222 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 186 | 62 |
| Alprazolam | Alprazolam | 159 | 50 |
| Methylprednisolone | Methylprednisolone | 151 | 112 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 145 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 144 | 48 |
| Omeprazole | Omeprazole | 137 | 55 |
| Simvastatin | Simvastatin | 127 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 49 |
| Metformin Hcl | Metformin Hcl | 114 | 37 |
| Furosemide | Furosemide | 108 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 44 |
| Gabapentin | Gabapentin | 84 | 46 |
| Losartan Potassium | Losartan Potassium | 82 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 28 |
| Montelukast Sodium | Montelukast Sodium | 72 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 36 |
| Ozempic | Semaglutide | 67 | 20 |
| Potassium Chloride | Potassium Chloride | 64 | 20 |
| Trazodone Hcl | Trazodone Hcl | 62 | 24 |
| Azithromycin | Azithromycin | 61 | 58 |
| Alendronate Sodium | Alendronate Sodium | 60 | 24 |
| Clonazepam | Clonazepam | 59 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 26 |
| Buspirone Hcl | Buspirone Hcl | 58 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 57 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 54 | 23 |
| Pregabalin | Pregabalin | 53 | 11 |
| Allopurinol | Allopurinol | 49 | 15 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 48 | 38 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 19 |
| Meloxicam | Meloxicam | 47 | 21 |
| Rybelsus | Semaglutide | 47 | 14 |
| Eliquis | Apixaban | 44 | 13 |
| Atenolol | Atenolol | 43 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 18 |
| Mupirocin | Mupirocin | 43 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 29 |
| Fenofibrate | Fenofibrate | 37 | 11 |
| Fluconazole | Fluconazole | 37 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 12 |
| Nystatin | Nystatin | 35 | 23 |
| Warfarin Sodium | Warfarin Sodium | 35 | 12 |
| Famotidine | Famotidine | 34 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 11 |
| Diazepam | Diazepam | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 24 |
| Baclofen | Baclofen | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | 12 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 11 |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 26 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Carvedilol | Carvedilol | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 11 |
| Estradiol | Estradiol | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | 12 |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | 13 |
| Lorazepam | Lorazepam | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Acetic Acid | Acetic Acid | 14 | 13 |
| Irbesartan | Irbesartan | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $324.30 · 18 records | Exact Sciences Corporation | Cologuard Collection Kit, ELIQUIS, NURTEC ODT, OTEZLA, REPATHA, TRELEGY ELLIPTA, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error